Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Argos Therapeutics
Argos Therapeutics develops personalized immunotherapies for cancer and infectious diseases.
Sector
Subsector
Location
total rounds
total raised
Affimed
Affimed is a clinical-stage biopharmaceutical company focused on targeted cancer immunotherapies.
Sector
Subsector
Keywords
Location
total rounds
total raised
Tizona Therapeutics
Tizona Therapeutics is developing treatments for cancer and autoimmune diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
IMV
IMV Inc. is developing a targeted immune therapy for cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds17
Number of Funding Rounds
Money Raised
Their latest funding was raised on 28.06.2024. Their latest round Post-IPO Equity
Gastro-Intestinal Research Foundation
For more than 50 years, we have devoted ourselves to making life better for patients and families living with digestive diseases.
Sector
Subsector
Keywords
Location
count Of Investments
Co-Investors
Investors8
Number of lead investors
Number of investors
Gastro-Intestinal Research Foundation
For more than 50 years, we have devoted ourselves to making life better for patients and families living with digestive diseases.
Sector
Subsector
Keywords
Location
count Of Investments
Angion Biomedica
Angion Biomedica is a clinical-stage biopharmaceutical company focused on restoring organs, with a particular focus on renal disease.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Access BridgeGap Ventures
Access Industries is a global industrial group with long-term investments.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Acquisitions1
Angion Biomedica acquired by Elicio Therapeutics
acquirer
date
type
Angion Biomedica
Angion Biomedica is a clinical-stage biopharmaceutical company focused on restoring organs, with a particular focus on renal disease.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
People
Founders3
Darrell Irvine
Darrell Irvine joined MIT as Professor in 2002.Darrell Irvine, Ph.D. Professor, Departments of Biological Engineering and Materials Science & Engineering Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology Ragon Institute of MGH, MIT, and Harvard Investigator, Howard Hughes Medical Institute.Biography: Darrell Irvine, Ph.D., is a Professor at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute. He also serves on the steering committee of the Ragon Institute of MGH, MIT, and Harvard. His research is focused on the application of engineering tools to problems in cellular immunology and the development of new materials for vaccine and drug delivery. Current efforts are focused on problems related to vaccine development for HIV and malaria, and immunotherapy of cancer. This interdisciplinary work has been recognized in numerous awards, including a Beckman Young Investigator award, an NSF CAREER award, selection for Technology Review’s ‘TR35’, election as a Fellow of the Biomedical Engineering Society, and appointment as an investigator of the Howard Hughes Medical Institute. He is the author of over 70 publications, reviews, and book chapters and an inventor on numerous patents.
current job
organization founded
Darrell Irvine
Satish Jindal
Satish Jindal, PhD, is BioMotiv’s CEO. Most recently, Dr. Jindal served as CEO of Allied-Bristol Life Sciences (ABLS). Prior to ABLS, he served as a Vice President at Bristol-Myers Squibb (BMS). Dr. Jindal has extensive experience in founding and building biotechnology companies, including Elicio Therapeutics Inc., an immunotherapy company that he co-founded based on intellectual property from the Koch Institute at the Massachusetts Institute of Technology (MIT); AntolRx, an immune tolerance company spun out from Harvard; Verastem Inc, a NASDAQ-listed Oncology company that he co-founded with researchers from the Whitehead Institute, the Broad Institute and MIT; and NeoGenesis Inc., a drug discovery company, he co-founded and served as its CEO, before its acquisition by Schering-Plough (now Merck) in 2005. He also served as Vice President and Site Head at Schering-Plough Research Institute in Cambridge, Massachusetts, and worked in Business Development at UCB Pharma in the UK. Dr. Jindal completed his postdoctoral work at Whitehead Institute for Biomedical Research at MIT and McMaster University in Hamilton, Ontario, Canada. He obtained a PhD in Biochemistry from Punjab University in India.
current job
Satish Jindal
Employee Profiles9
Joy Seymour
Vice President, Head of Regulatory Affairs
Christopher Haqq
Executive Vice President, Head of Research & Development
Daniel Geffken
Interim Chief Financial Officer and Director
Activity
Recent News11
The graph reveals the ratio (%) of positive news articles in a chosen time range